Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a

British Journal of Cancer

Volumn 78, Issue 8, 1998, Pages 1076-1080

  Hoffmann, R ^a   Muller, I ^a   Neuber, K ^a   Lassmann, S ^a   Buer, J ^a   Probst, M ^a   Oevermann, K ^a   Franzke, A ^a   Kirchner, H ^a   Ganser, A ^a   Atzpodien, J ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemotherapy; Immunotherapy; Metastatic melanoma; Prognosis; Treatment

Indexed keywords

ALPHA2A INTERFERON; CARMUSTINE; CISPLATIN; DACARBAZINE; INTERLEUKIN 2; LACTATE DEHYDROGENASE; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; OUTPATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

EID: 0031712752     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.630     Document Type: Article

References (13)